{"name":"KunWha Pharmaceutical Co., Ltd.","slug":"kunwha-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"KunWha Pharmaceutical Co., Ltd. is a pharmaceutical company with a focus on developing and commercializing innovative drugs. The company has a pipeline of four drugs, including KW21052 and Lyrica (low dose), both in Phase 3 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Placebo of KW21052","genericName":"Placebo of KW21052","slug":"placebo-of-kw21052","indication":"Other","status":"phase_3"},{"name":"Placebo of Lyrica","genericName":"Placebo of Lyrica","slug":"placebo-of-lyrica","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KW21052","genericName":"KW21052","slug":"kw21052","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Lyrica (low dose)","genericName":"Lyrica (low dose)","slug":"lyrica-low-dose","indication":"Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia)","status":"phase_3"}]}],"pipeline":[{"name":"KW21052","genericName":"KW21052","slug":"kw21052","phase":"phase_3","mechanism":"KW21052 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Lyrica (low dose)","genericName":"Lyrica (low dose)","slug":"lyrica-low-dose","phase":"phase_3","mechanism":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","indications":["Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia)","Partial-onset seizures (adjunctive therapy)","Fibromyalgia","Generalized anxiety disorder"],"catalyst":""},{"name":"Placebo of KW21052","genericName":"Placebo of KW21052","slug":"placebo-of-kw21052","phase":"phase_3","mechanism":"This is a placebo control and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of Lyrica","genericName":"Placebo of Lyrica","slug":"placebo-of-lyrica","phase":"phase_3","mechanism":"This is a placebo control formulation used in clinical trials to compare against the active drug Lyrica (pregabalin).","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxORGJrNVZoNUhJOTRmNnhteE5OQmUyNlBWNVpUeGUteGRNVnJLT0NGOUpvQmZyWFZfUldQbHpQOG9NWmMzRWVGZHAxNHVkX19uWXBvTTYxNGthV3Jxby1FWHhHcFpJeEZYWG1UWWs3VjV1SWd4aHRlV2RyVXA4eXNWcTF4bUxUMFpMYWJUSEpZVGk5bUtzaUt2cnFqTmU1TFpNLXd4b1pCOHA4cHlPQk5kSmVjbjJoemJYQ1NrMFA4a2dUbXdfMXVqdk9hRkFPazlUeUVyT0NsTDc2bEgxZTZLTzJ5VkZPWUFkbkxObENTalhONjR1N1FfT2x3?oc=5","date":"2010-05-27","type":"regulatory","source":"RTTNews","summary":"BioDelivery Sciences Enters Into License And Supply Agreement With Kunwha Pharma For BEMA Fentanyl In South Korea - Quick Facts - RTTNews","headline":"BioDelivery Sciences Enters Into License And Supply Agreement With Kunwha Pharma For BEMA Fentanyl In South Korea - Quic","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}